好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2026 Annual Meeting | Clinical Trials Popcorn Plenary Session

Tuesday 04/21/26
11:30 AM - 12:00 PM CDT Add To Calendar
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Hubs (Practice and Policy)
Sarah M. Benish, MD, FAAN
Practice, Policy, and Ethics
Practitioners are invited to continue the conversation from the Clinical Trials Plenary Session. Join us as we break down the key points from the plenary and explain how physicians and advanced practice providers can use and/or relate to this content presented.
No CME available
Patient Care & Procedural Skills, Practice-based Learning and Improvement, Systems-based Practice
Intermediate
Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student
Audience Participation
Event Timeline
11:30 AM - 12:00 PM CDT Discussion Clinical Trials Popcorn Plenary Session
Sarah M. Benish, MD, FAAN, Michael Phipps, MD, MHS, FAAN
Faculty Disclosures
Kinga Tomczak, MD, PhD The institution of Dr. Tomczak has received research support from Emalex Biosciences, Inc.. Dr. Tomczak has a non-compensated relationship as a collabolator with Emalex Biosciences, Inc. that is relevant to AAN interests or activities.
Sarah M. Benish, MD, FAAN Dr. Benish has received personal compensation in the range of $500-$4,999 for serving as a Conference Speaker with Optum Health 好色先生.
Jill M. Farmer, DO, MPH Dr. Farmer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. Dr. Farmer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Supernus. Dr. Farmer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurocrine. Dr. Farmer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Acadia. Dr. Farmer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie. Dr. Farmer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amneal. Dr. Farmer has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Live. The institution of Dr. Farmer has received research support from Parkinson's Foundation.
Amy T. Waldman, MD Dr. Waldman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SwanBio. An immediate family member of Dr. Waldman has or had stock in Pfizer. The institution of Dr. Waldman has received research support from Ionis Pharmaceuticals. The institution of Dr. Waldman has received research support from Roche/Genentech. The institution of Dr. Waldman has received research support from Ionis Pharmaceuticals. The institution of Dr. Waldman has received research support from Calico. Dr. Waldman has received publishing royalties from a publication relating to health care. Dr. Waldman has received publishing royalties from a publication relating to health care.
Tuan H. Vu, MD Dr. Vu has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Dianthus. Dr. Vu has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Vu has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NMD Pharma. Dr. Vu has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ARGENX. Dr. Vu has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Vu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Vu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen (Horizon). Dr. Vu has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Johnson. Dr. Vu has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Alexion. Dr. Vu has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for CSL Behring. Dr. Vu has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. The institution of Dr. Vu has received research support from CSL Behring. The institution of Dr. Vu has received research support from Alexion. The institution of Dr. Vu has received research support from RA Pharma/UCB. The institution of Dr. Vu has received research support from Mass Gen Hospital/Healy Platform Study. The institution of Dr. Vu has received research support from ARGENX. The institution of Dr. Vu has received research support from Horizon/Amgen. The institution of Dr. Vu has received research support from Woolsey Pharma. The institution of Dr. Vu has received research support from CSL Behring. The institution of Dr. Vu has received research support from Cartesian Therapeutics. The institution of Dr. Vu has received research support from Janssen/Johnson & Johnson. The institution of Dr. Vu has received research support from Immunovant. The institution of Dr. Vu has received research support from Regeneron. The institution of Dr. Vu has received research support from Dianthus. The institution of Dr. Vu has received research support from COUR.
Pablo Villoslada, MD, PhD, FAAN Dr. Villoslada has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Oculis. Dr. Villoslada has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bionure. Dr. Villoslada has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Telara Therapeutics. Dr. Villoslada has or had stock in Attune Neurosciences.Dr. Villoslada has or had stock in Bionure Therapeutics.Dr. Villoslada has or had stock in Spiral Therapeutics.Dr. Villoslada has or had stock in Adhera Health.Dr. Villoslada has or had stock in Clarity technologies.Dr. Villoslada has or had stock in QMENTA Inc. The institution of Dr. Villoslada has received research support from Start2Cure Foundation. The institution of Dr. Villoslada has received research support from European Commission. The institution of Dr. Villoslada has received research support from Instituto Salud Carlos III. The institution of Dr. Villoslada has received research support from Focused Ultrasound Foundation and ALS Foundation. The institution of Dr. Villoslada has received research support from Caixa Foundation. Dr. Villoslada has received intellectual property interests from a discovery or technology relating to health care.
Michael Phipps, MD, MHS, FAAN Dr. Phipps has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMJ.